Cognitive Research Corporation
Comprehensive CRO Services for Central Nervous System Products

Although contract research organization (CRO) service models have evolved enormously over the past few decades, they still cater primarily to the requirements of large, international pharmaceutical companies. Partnering with traditional CROs is often expensive, cumbersome, and time-consuming, highlighting the reality that they don’t modify their offerings to accommodate the diverse operational requirements of small and medium companies. Changing this narrative is Florida-headquartered, industry expert Cognitive Research Corporation (CRC). The company provides small and mid-size, as well as enterprise pharmaceutical companies with solid scientific acumen that helps them test the efficacy of their compounds and develop commercially viable products.

Cognitive Research Corporation is a therapeutically focused clinical service provider, specializing in the development of Central Nervous System (CNS) drugs. Having developed an integrated network of research facilities across the nation, CRC is proficient in conducting clinical studies at any given stage, from Phase I to IV. CRC’s team of seasoned experts and board-certified neuropsychologists bring over four decades of extensive domain experience to deliver repeatable excellence.

As an eminent player in the pharmaceutical arena, CRC offers a flexible yet comprehensive services portfolio, including clinical trial management, biostatistics, trial design, medical writing, and regulatory affairs. Its high-touch service model forges strong relationships with its clients. CRC’s team infuses exceptional levels of safety, cost-effectiveness, and reliability into its services, empowering clients to seamlessly accomplish clinical trial objectives.

“CRC’s employee turnover is under 10 percent. Clients get to work with the same people, build relationships and trust, ultimately creating more efficient clinical trials,” says C.G. “Chip” Gillooly, CEO.

The teams have completed over 500 trials across all areas in the CNS space, substantiating the company’s reputation.

CRC developed methods to study the effects of experimental compounds for mental illnesses, with expertise in a wide range of CNS indications, including Alzheimer’s, Parkinson’s, schizophrenia, and depression. The company has proprietary rights to the psychometric technologies CogScreen^® and CRC Driving Simulators (CRCDS), which provide unique capabilities to evaluate drug effects on cognition.

CogScreen^® is one of the world’s leading computerized neuropsychological test batteries, designed to analyze the variations in attention, visual perceptual functions, and more. The technology was developed by Dr. Gary G. Kay, Chief Scientific Officer at CRC, for the U.S. Federal Aviation Administration, to detect subtle changes in cognitive functions in pilots. CRC has also developed a customizable driving simulator, CRCDS, to analyze the effects of age, neurological diseases, alcohol toxicity, fatigue, and trauma on driving performances. These products have proven to be highly sensitive to therapeutic and drug effects, precisely measuring cognitive variations.

CRC has built a culture based on high morale and scientific expertise, enabling it to deliver the highest value to its clients, which is supported by the fact that many of CRC’s clients rely on them for all their clinical development needs. For example, BioXcel Therapeutics, one of the pioneers in the global biotechnology industry, partnered with CRC on the FDA approval of IGALMI^™ (dexmedetomidine) sublingual film for treating schizophrenia and bipolar disorders from first-in-human trials all the way to FDA approval.

Reinforcing the company’s experience and innovation in the CNS space, CRC is working with clients in assisted living facilities across the U.S. to evaluate new drugs for early onset and various facets of dementia. Propelled by rapid strides recent years, Cognitive Research Corporation will continue to expand and bear the torch to foster innovation and customer-centricity in the CNS firmament, empowering emerging biotechs and drug companies to bring new medicines and therapies to the global challenges in mental health.